



## Supplier Qualifier Report

[Print this Report](#)

Copyright 2022 Dun & Bradstreet - Provided under contract for the exclusive use of subscriber 263159923

ATTN: **Name1**

Report Printed: NOV 18 2022  
**In Date**

### BUSINESS INFORMATION

#### LABORATORY CORPORATION OF AMERICA HOLDINGS

LABCORP  
**358 S Main St**  
**Burlington, NC 27215**

Do not confuse with its subsidiary of similar name.  
This is a **headquarters** location.  
Branch(es) or division(s) exist.

**Mailing address:** PO Box 8601  
Burlington, NC 27216

**Telephone:** 336 229-1127

**Chief executive:** ADAM H SCHECHTER, CHB-  
PRES-CEO

**Stock symbol:** LH

**Year started:** 1971

**Employs:** 75,500 (2,000 here)

All amounts are displayed in local currency.

#### Financial statement

**date:** SEP 30 2022

**Net worth:** 10,273,400,000

**Gross revenue F:** 16,120,900,000

**History:** CLEAR

**Financial condition:** GOOD

**D-U-N-S® Number:** 86-142-2434


**D&B Rating:** **5A2**

**Financial strength:** 5A is **\$50 million and over.**

**Composite credit appraisal:** 2 is **good.**

**D&B Supplier Risk:** **2**


#### SUPPLIER EVALUATION RISK (SER) RATING FOR THIS FIRM : **2**



### D&B PAYDEX®

#### D&B PAYDEX: **75**

When weighted by dollar amount, payments to suppliers average 8 days beyond terms.



Based on up to 24 months of trade.

### SUMMARY ANALYSIS

**D&B Rating:** **5A2****Financial strength:** 5A indicates **\$50 million and over.****Composite credit appraisal:** 2 is **good.**

This credit rating was assigned because of D&B's assessment of the company's financial ratios and its cash flow. For more information, see the D&B Rating Key.

Below is an overview of the company's rating history since 08/18/94:

D&B Rating	Date Applied
5A2	02/27/15
5A1	01/26/15
5A2	04/27/01
--	08/18/94

The Summary Analysis section reflects information in D&B's file as of November 14, 2022.

## RISK SCORE ANALYSIS

### SER COMMENTARY:

- Change in net worth.
- Proportion of slow payment experiences to total number of payment experiences reported.
- Business belongs to an industry with above average risk of ceasing operations or becoming inactive.

## PROBABILITY OF CEASED OPERATIONS/BECOMING INACTIVE

### SUPPLIER EVALUATION RISK RATING: 2

The probability of ceased operations/becoming inactive indicates what percent of U.S. businesses is expected to cease operations or become inactive over next 12 months.

**Probability of Supplier Ceased Operations/Becoming Inactive :** 2.1% (210 PER 10,000)

**Percentage of US business with same SER score :** 15% (1,500 PER 10,000)

**Average Probability of Supplier Ceased Operations/Becoming Inactive :** 0.48% (48 PER 10,000)  
- Average of Businesses in D&B's Supplier Database

**CREDIT DELINQUENCY SCORE:** 506

## SPECIAL EVENTS

11/18/2022

**EARNINGS UPDATE:** According to published reports, comparative operating results for the 9 months ended September 30, 2022: Revenue of \$11,202,600,000, Net Income of \$1,204,200,000; compared to Revenue of \$12,064,800,000, Net Income of \$1,825,900,000 for the comparable period in the prior year.

10/24/2022

**PURCHASE OF ASSET:** According to published reports, Labcorp, DUNS 861422434, (Burlington, NC) announced that it has purchased select assets of Ascensions, DUNS 077126852, (Saint Louis, MO) outreach laboratory business.

08/03/2022

**EARNINGS UPDATE:** According to published reports, comparative operating results for the 6 months ended June 30, 2022: Revenue of \$7,596,500,000, Net Income of \$851,000,000; compared to Revenue of \$8,002,200,000, Net Income of \$1,238,100,000 for the comparable period in the prior year.

07/25/2022

**ANNOUNCED WORK FORCE CHANGES:** According to published reports, Labcorp announced an expansion of its automated clinical trial kit production line in Mechelen, Belgium. Once completed, expansion will allow for clinical trial test kits to be fulfilled in Mechelen for more than 70 countries throughout Europe, the Middle East and Africa.

05/27/2022

**WORK FORCE CHANGES:** According to published reports, Labcorp announced that it has opened its new location at 3424 N. Tarrant Parkway, Ste. 410, Fort Worth, on March 21.

05/05/2022

**EARNINGS UPDATE:** According to published reports, comparative operating results for the 3 months ended March 31, 2022: Revenue of \$3,899,600,000, Net Income of \$492,100,000; compared to Revenue of \$4,161,500,000, Net Income of \$770,100,000 for the comparable period in the prior year.

## CUSTOMER SERVICE

If you have questions about this report, please call our Customer Resource Center at 1.800.234.3867 from anywhere within the U.S. If you are outside the U.S. contact your local D&B office.

\*\*\* Additional Decision Support Available \*\*\*

Additional D&B products, monitoring services and specialized investigations are available to help you evaluate this company or its industry. Call Dun & Bradstreet's Customer Resource Center at 1.800.234.3867 from anywhere within the U.S. or visit our website at [www.dnb.com](http://www.dnb.com).

## HISTORY

The following information was reported **03/23/2022**:

**Officer(s):** ADAM H SCHECHTER, CHB-PRES-CEO+  
GLENN A EISENBERG, EXEC V PRES-CFO  
LANCE V BERBERIAN, EXEC V PRES-CHIEF INFO & TECH OFFICER  
JUDITH C SELTZ, EXEC V PRES-CHIEF HR OFFICER  
AMY B SUMMY, EXEC V PRES-CMO  
SANDRA D VAN DER VAART, EXEC V PRES-CLO-CCO-SEC  
PETER J WILKINSON, SR V PRES-CAO

**DIRECTOR(S):** The officers identified by (+) and Kerri B Anderson, Jean-Luc Belingard, Jeffrey A Davis, D Gary Gilliland, Garheng Kong, Peter M Neupert, Richelle Parham, Kathryn E Wengel and R Sanders Williams.

The Delaware Secretary of State's business registrations file showed that Laboratory Corporation of America Holdings was registered as a Corporation on March 8, 1994, under file registration number 2384108.

Business started 1971.

The company (LabCorp) was originally known as DCL Health Laboratories Incorporated, was founded in 1971 as a subsidiary of Revlon Inc. On May 28, 1974 the name was changed to National Health Laboratories Incorporated (NHL). In 1988, the company completed an initial public stock offering, with a second offering in 1991 reducing Revlon's ownership to less than 50%. On April 28, 1995, the company completed a merger with Roche Biomedical Laboratories Inc. (indirect subsidiary of Roche Holdings Inc). In connection with the merger, the company changed its name from National Health Laboratories to Laboratory Corporation of America Holdings.

The company's common stock is traded on the New York Stock Exchange (NYSE) under the symbol "LH". As of February 24, 2022, there were approximately 1,322 holders of record of the company's common stock. As of March 24, 2021, the most recent date available, those shareholders identified by the company as beneficially owning 5% or more of the outstanding shares were: The Vanguard Group, Inc (10.68%); and BlackRock, Inc (8.0%). As of the same date, officers and directors as a group beneficially owns less than 1% of the total outstanding shares.

## RECENT EVENTS:

On March 22, 2022, sources stated that Laboratory Corp of America Holdings d/b/a Labcorp, Burlington, NC, has acquired Personal Genome Diagnostics Inc., Baltimore, MD, on February 18, 2022. With the acquisition, Personal Genome Diagnostics Inc. will now operate as a subsidiary of Laboratory Corp of America Holdings. Employees and management were retained. Under the terms of the agreement, Labcorp paid \$450.0 in cash at closing and up to an additional \$125.0 on achieving future performance milestones. Further details are unavailable.

During the year ended December 31, 2021, the company acquired various businesses and related assets for approximately \$496.9 in cash.

On December 3, 2021, the company completed the acquisition of Toxikon Corporation. With the acquisition, Toxikon Corporation has converted into a Delaware Limited Liability Company, under the name Toxikon, LLC. Subsequently, Toxikon, LLC has changed its name to Labcorp Bedford LLC and will now operate as a subsidiary of the company.

On September 23, 2021, the company, through its wholly owned subsidiary Medtox Diagnostics, Inc., acquired the assets of Sandstone Diagnostics, Inc. With the acquisition, Sandstone Diagnostics, Inc. has remained as a separate legal entity and the acquired assets will be integrated to Medtox Diagnostics, Inc.

On September 7, 2021, the company acquired select operating assets and intellectual property from Myriad Genetics,

Inc.,.

On August 12, 2021, the company acquired Ovuline, Inc., d/b/a Ovia Health. With the acquisition, Ovuline, Inc. will now operate as a subsidiary of the company.

During the three months ended March 31, 2021, the company acquired a business and related assets for approximately \$34.1 in cash within Dx.

ADAM H SCHECHTER. He has served as a Director since April 2013 and as the President and CEO of the company since November 2019. Prior to that, he was the Executive Vice President of Merck & Co, Inc. from 2010 to 2018. He served as a special advisor to the CEO of Merck from January 2019 to July 2019. He previously served as the President of Merck's Global Human Health Division from 2010 to 2018.

GLENN A EISENBERG. He has served as the Executive Vice President and CFO since June 2014. From 2002 until joining the company, he served as the Executive Vice President of Finance and Administration and CFO at The Timken Company.

LANCE V BERBERIAN. He has served as the Executive Vice President and Chief Information and Technology Officer since February 2020. Prior to that, he served as the Senior Vice President and Chief Information Officer from February 2014. Prior to joining the company, he served as the CIO at IDEXX Laboratories, Inc. from 2007 to 2014.

JUDITH C SELTZ. She has served as the Executive Vice President and Chief Human Resources Officer since February 2020. From October 2019 until then, she served as the Senior Vice President and Chief Human Resources Officer. She previously served as Chief Human Resources Officer at Diversey Inc from October 2018 until July 2019.

AMY B SUMMY. She has served as the Executive Vice President and Chief Marketing Officer (CMO) since March 2020. Prior to joining the company, she was a Partner, Marketing & Insights Practice Leader for the Americas for Ernst & Young LLP, from February 2018 to February 2020. From January 2013 to January 2018, she was the Senior Vice President and CMO for TE Connectivity Ltd., a technology and manufacturing company. Prior to that, she was the Senior Vice President from July 2011 to December 2012.

SANDRA D VAN DER VAART. She has served as the Executive Vice President, Chief Legal Officer (CLO), Chief Compliance Officer (CCO) and Corporate Secretary since February 2020. Since 2001, she has held several positions with the company.

PETER J WILKINSON. He has served as the Senior Vice President and CAO since April 2019. From January 2019 until then, he served in the role of company's Senior Vice President, Accounting. Prior to that, he served as the Executive Vice President and CFO of Syneos Health, Inc's clinical division, from August 2017 to July 2018 and as the Senior Vice President and CAO of INC Research Holdings, Inc from February 2016 to August 2017. He also previously served as the Senior Vice President in the INC Research finance department from April 2014 to February 2016. Prior to his position with INC Research, he worked as a self-employed financial consultant, following earlier positions as the CAO at Pharmaceutical Product Development, LLC and as an Auditor with Deloitte & Touche LLP.

KERRI B ANDERSON. Director since May 2006. She was the CEO of Wendy's International, Inc. from April 2006 until September 2008.

JEAN-LUC BELINGARD. Director since April 1995. He serves currently as the Operating Advisor to Clayton, Dubilier & Rice since October 2019.

JEFFREY A DAVIS. Director since December 2019. He currently serves as the CFO of Qurate Retail Group since October 2018.

D GARY GILLILAND. Director since April 2014. He has served as the President and as a Director Emeritus of the Fred Hutchinson Cancer Research Center since January 2020.

GARHENG KONG. Director since December 2013. He has been a Managing Partner of HealthQuest Capital, a firm he founded in 2012.

PETER M NEUPERT. Director since January 2013. He was an Operating Partner at Health Evolution Partners from January 2012 until June 2015.

RICHELLE PARHAM. Director since February 2016. In October 2019, she became a Managing Director of WestRiver Group.

KATHRYN E WENGEL. Director since March 2021. She currently serves as the Executive Vice President, Chief Global Supply Chain Officer and as an Executive Committee member and Executive Officer of Johnson & Johnson since July 2018.

R SANDERS WILLIAMS. Director since May 2007. He currently serves as Vice President for Research and Innovation (Interim) of Duke University.

---

## BUSINESS REGISTRATION

CORPORATE AND BUSINESS REGISTRATIONS REPORTED BY THE SECRETARY OF STATE OR OTHER OFFICIAL SOURCE AS OF MAY 19 2012:

**Registered Name:** LABORATORY CORPORATION OF AMERICA HOLDINGS

**Business type:** CORPORATION

**Corporation type:** NOT AVAILABLE

**Date incorporated:** MAR 08 1994

**State of incorporation:** DELAWARE

**Filing date:** MAR 08 1994

**Registration ID:** 2384108

**Status:** STATUS NOT AVAILABLE

**Where filed:** SECRETARY OF STATE/CORPORATIONS DIVISION, DOVER, DE

**Registered agent:** CORPORATION SERVICE COMPANY, 2711 CENTERVILLE ROAD SUITE 400, WILMINGTON, DE, 198080000

## OPERATIONS

03/23/2022

**Description:** The company operates as an independent clinical laboratory company. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests.

Terms vary by contract and reimbursement procedures per client or account. Sells to general public, commercial concerns and government. Territory : International.

The company experiences seasonality across its business. For example, testing volume generally declines during the year-end holiday period and other major holidays and can also decline due to inclement weather or natural disasters. Declines in testing volume reduce revenues, operating margins and cash flows. Operations are also impacted by changes in the global economy, exchange rate fluctuations, political and regulatory changes, the progress of ongoing studies and the startup of new studies, as well as the level of expenditures made by the biopharmaceutical industry in R&D.

**Employees:** 75,500 which includes officer(s). 2,000 employed here.

**Facilities:** Occupies premises in a building. The company's corporate headquarters are located in Burlington, NC that includes facilities that are both owned and leased.

**Subsidiaries:** The business has subsidiary(ies); detailed subsidiary information is available in Dun & Bradstreet's linkage or family tree products.

## FAMILY LINKAGE

This business is at the head of its corporate family tree. It is not a subsidiary of any other business.

## UNSPSC

UNSPSC (United Nations Standard Product and Services Code) is a globally accepted commodity (Product and Services) classification system. LABORATORY CORPORATION OF AMERICA HOLDINGS offers the following product(s) and service(s):

**85121800 Medical laboratories**

## NAICS

Beginning in 1997, the **Standard Industrial Classification** (SIC) was replaced by the **North American Industry**

**Classification System** (NAICS). This six digit code is a major revision that not only provides for newer industries, but also reorganizes the categories on a production/process-oriented basis. This new, uniform, industry-wide classification system has been designed as the index for statistical reporting of all economic activities of the U.S., Canada, and Mexico.

## 621511 Medical Laboratories

### SIC

Based on information in our file, D&B has assigned this company an extended 8-digit SIC. D&B's use of 8-digit SICs enables us to be more specific to a company's operations than if we use the standard 4-digit code.


## 80710100 Testing laboratories

### D&B PAYDEX

The D&B PAYDEX is a unique, dollar weighted indicator of payment performance based on up to 138 payment experiences as reported to D&B by trade references.

#### 3-Month D&B PAYDEX: 75


When weighted by dollar amount, payments to suppliers average 8 days beyond terms.



Based on trade collected over last 3 months.

#### D&B PAYDEX: 75

When weighted by dollar amount, payments to suppliers average 8 days beyond terms.



Based on up to 24 months of trade.  
When dollar amounts are not considered, then approximately 72% of the company's payments are within terms.

### PAYMENT SUMMARY

The Payment Summary section reflects payment information in D&B's file as of the date of this report.

Below is an overview of the company's dollar-weighted payments, segmented by its suppliers' primary industries:

	Total Rcv'd (#)	Total Dollar Amts (\$)	Largest High Credit (\$)	Within Terms (%)	Days Slow <31 31-60 61-90 90> (%)			
Top industries:								
Public finance	21	69,700	55,000	100	-	-	-	-
Telephone communictns	16	2,231,600	500,000	99	-	1	-	-
Nonclassified	6	145,350	90,000	41	-	-	59	-
Misc business credit	3	2,050,000	2,000,000	100	-	-	-	-
Radiotelephone commun	3	440,000	400,000	55	-	-	-	45
Whol computers/softwr	2	115,000	80,000	15	15	70	-	-
Mfg medical instrmnt	1	250,000	250,000	50	-	-	-	50
Ret computer/software	1	100,000	100,000	100	-	-	-	-
Custom programming	1	75,000	75,000	100	-	-	-	-
Mfg electromedcl prdt	1	40,000	40,000	50	-	50	-	-
OTHER INDUSTRIES	40	168,800	30,000	89	3	-	2	6
Other payment categories:								
Cash experiences	34	2,700	1,000					
Payment record unknown	5	8,550	5,000					
Unfavorable comments	1	250	250					

**Placed for collections:**

With D&B	0	0	
Other	3	N/A	
Total in D&B's file	138	5,696,950	2,000,000

The highest **Now Owes** on file is \$2,000,000

The highest **Past Due** on file is \$200,000

Dun & Bradstreet has 138 payment experiences in its file for this company. For your convenience, we have displayed 80 representative experiences in the PAYMENTS section.

**PAYMENT DETAILS****Detailed payment history**

Date Reported (mm/yy)	Paying Record	High Credit (\$)	Now Owes (\$)	Past Due (\$)	Selling Terms	Last Sale Within (months)
11/22	Ppt	2,000,000	2,000,000	0		1 mo
	Ppt	25,000	25,000	0		1 mo
10/22	Ppt	25,000	25,000	0		1 mo
	Ppt	15,000	0	0		2-3 mos
	Ppt	15,000	0	0		6-12 mos
	Ppt	5,000	0	0		1 mo
	Ppt	5,000	2,500	0		1 mo
	Ppt	2,500	0	0		4-5 mos
	Ppt	2,500	0	0		6-12 mos
	Ppt	2,500	0	0	N30	4-5 mos
	Ppt	2,500	2,500	0		1 mo
	Ppt	2,500	1,000	0		1 mo
	Ppt	1,000	500	0		1 mo
	Ppt	1,000	750	0		1 mo
	Ppt	500	100	0		1 mo
	Ppt	100	0	0		4-5 mos
	Ppt	50	0	0	N30	1 mo
	Ppt	0	0	0		1 mo
	Ppt-Slow 30	7,500	5,000	0	N30	1 mo
	Ppt-Slow 30	1,000	1,000	0	N30	1 mo
	Ppt-Slow 30	250	100	0	N30	1 mo
	Ppt-Slow 90	7,500	0	0	2 10 N30	4-5 mos
09/22	Slow 30	750	0	0		2-3 mos
	Slow 30	250	0	0		6-12 mos
	Slow 120	1,000	0	0		6-12 mos
	(026)				Cash account	6-12 mos
	(027)				Cash account	6-12 mos
	(028)	750	0	0		1 mo
	(029)	50			Cash account	1 mo
	Ppt	400,000	300,000	0		1 mo
	Ppt	200,000	200,000	0		1 mo
	Ppt	30,000	0	0		6-12 mos
	Ppt	15,000	15,000	0		1 mo
	Ppt-Slow 60	45,000	0	0		2-3 mos

	Ppt-Slow 90	500	500	250		1 mo
	Ppt-Slow 90+	400,000	400,000	200,000		1 mo
	Ppt-Slow 150	250	100	0		1 mo
	Slow 30-120	100	0	0		2-3 mos
	Slow 30-150	5,000	5,000	5,000		1 mo
	(040)	2,500	0	0		6-12 mos
	(041)	100			Cash account	4-5 mos
	(042)	50			Cash account	1 mo
	(043)	50				1 mo
08/22	Ppt	750				1 mo
	(045)	750	750	750		
	Placed for collection.					
	(046)	100			Cash account	4-5 mos
07/22	Ppt	500				1 mo
	Ppt	250				1 mo
	Ppt	250				1 mo
	Ppt	250				1 mo
	Ppt	100				1 mo
06/22	Ppt	400,000	200,000	0		1 mo
	Ppt	200,000	200,000	0		1 mo
	Ppt	55,000				1 mo
	Ppt	250				1 mo
	Ppt	100				1 mo
	Ppt	100				1 mo
05/22	(058)	100	100	100		
	Placed for collection.					
02/22	Ppt	7,500	0	0		2-3 mos
	Ppt	2,500				1 mo
	Ppt	250				1 mo
	Ppt	250				1 mo
	Ppt	250				1 mo
	Ppt	50	0	0		6-12 mos
01/22	Ppt					1 mo
	Ppt-Slow 60	40,000	20,000	0		1 mo
12/21	Ppt					1 mo
	Ppt					1 mo
	Ppt					1 mo
	Ppt					1 mo
	Slow 120-180	50	50	50		4-5 mos
10/21	Ppt	2,500	0	0		6-12 mos
06/21	Ppt	5,000				1 mo
	Ppt	250	0	0		6-12 mos
	(075)	250	250	250		
	Placed for collection.					
05/21	Ppt	7,500				1 mo
	Ppt	500				1 mo
	Ppt	100				1 mo
02/21	Ppt	50	0	0		6-12 mos
	Ppt-Slow 90	90,000	20,000	15,000		1 mo

Accounts are sometimes placed for collection even though the existence or amount of the debt is disputed.

Payment experiences reflect how bills are met in relation to the terms granted. In some instances payment beyond terms can be the result of disputes over merchandise, skipped invoices etc.

Each experience shown is from a separate supplier. Updated trade experiences replace those previously reported.

#### PAYMENT TRENDS



**SUPPLIER VERSUS INDUSTRY PAYDEX**

->	PRIOR 4 QTRS				CURRENT 12 MONTH TREND											
	2020	2021	---	---	---	2022	---	---	---	---	---	---	---	---	---	---
	DEC	MAR	JUN	SEP	DEC	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV
Supplier PAYDEX	79	78	79	78	76	76	75	75	75	75	75	74	76	75	75	75
<b>Industry PAYDEX (Based on 17 establishments in SIC 8071)</b>																
UP QRT	79	79	79	79	79			79			79			79		
MEDIAN	74	74	73	74	74			74			74			75		
LO QRT	64	64	66	67	67			68			68			67		

PAYDEX scores are updated daily and are based on upto 24 months of trade experiences from the Dun& Bradstreet trade file.

**All amounts displayed within this report are in local currency.**

**STATEMENT UPDATE**

**11/02/2022**

**Interim Consolidated statement dated SEP 30 2022 (in thousands):**

<b>Assets</b>				<b>Liabilities</b>			
Cash		409,900		Accts Pay		765,500	
Accts Rec		2,164,200		Unearned Revenue		530,900	
Inventory		467,700		Accruals		1,040,800	
Unbilled Services		818,500		Operating Lease Liabilities		178,100	
Prepaid		511,500		Finance Lease Liabilities		5,300	
				Other Curr Liabs		1,700	
<b>Curr Assets</b>		<b>4,371,800</b>		<b>Curr Liabs</b>		<b>2,522,300</b>	
Fixt & Equip		2,884,700		Operating Lease Liabilities		665,900	
Goodwill-Net		8,217,600		Financing Lease Liabilities		85,800	
Investments-Other		63,700		L.T. Liab-Other		6,459,800	
Intangible Assets-Net		3,807,800		ADDIT. PD.-IN CAP		8,200	
Deferred Income Taxes		29,400		ACCUM OTHER COMPREHENSIVE LOSS		(761,000)	
Other Assets		451,000		RETAINED EARNINGS		10,845,000	
<b>Total Assets</b>		<b>19,826,000</b>		<b>Total</b>		<b>19,826,000</b>	

From JAN 01 2022 to SEP 30 2022 sales \$11,202,600,000; cost of goods sold \$7,787,300,000. Gross profit \$3,415,300,000; operating expenses \$1,732,100,000. Operating income \$1,683,200,000; other income \$13,700,000; other expenses \$158,800,000; net income before taxes \$1,538,100,000; Federal income tax \$333,900,000; net income \$1,204,200,000.

Statement obtained in outside quarters. Statement obtained from Securities and Exchange Commission. Prepared from books without audit.

Accounts receivable shown net less \$20,500,000 allowance.

**Explanations**

The net worth of this company includes intangibles; Other Long Term Liabilities consists of long-term debt, deferred income taxes & other tax liabilities, other liabilities and noncontrolling interest.

**FINANCE****03/11/2022****Three-year statement comparative:**

	<b>Fiscal Consolidated Dec 31 2019 (000s omitted)</b>	<b>Fiscal Consolidated Dec 31 2020 (000s omitted)</b>	<b>Fiscal Consolidated Dec 31 2021 (000s omitted)</b>
Current Assets	2,981,200	5,125,400	5,330,500
Current Liabs	2,655,800	3,078,500	2,782,900
Current Ratio	1.12	1.66	1.92
Working Capital	325,400	2,046,900	2,547,600
Other Assets	15,065,200	14,946,300	15,054,900
Net Worth	7,567,000	9,436,600	10,273,400
Sales	11,554,800	13,978,500	16,120,900
Long Term Liab	7,823,600	7,556,600	7,329,100
Net Profit (Loss)	824,900	1,557,000	2,379,500

**Fiscal Consolidated statement dated DEC 31 2021:**

<b>Assets</b>		<b>Liabilities</b>	
Cash	1,472,700	Accts Pay	621,300
Accts Rec	2,261,500	Unearned Revenue	558,500
Inventory	401,400	Accruals	1,404,100
Unbilled Services	716,800	Operating Lease Liabilities	187,000
Prepaid	478,100	Finance Lease Liabilities	10,500
		Other Curr Liabs	1,500
<b>Curr Assets</b>	<b>5,330,500</b>	<b>Curr Liabs</b>	<b>2,782,900</b>
Fixt & Equip	2,815,400	Operating Lease Liabilities	642,500
Goodwill-Net	7,958,900	Financing Lease Liabilities	84,600
Investments-Other	60,900	L.T. Liab-Other	6,602,000
Intangible Assets-Net	3,735,500	COMMON STOCK	8,500
Deferred Income Taxes	21,600	ACCUM OTHER COMPREHENSIVE LOSS	(191,900)
Other Assets	462,600	RETAINED EARNINGS	10,456,800
<b>Total Assets</b>	<b>20,385,400</b>	<b>Total</b>	<b>20,385,400</b>

Sales \$16,120,900,000; cost of goods sold \$10,496,600,000. Gross profit \$5,624,300,000; operating expenses \$2,364,800,000. Operating income \$3,259,500,000; other income \$79,200,000; other expenses \$212,100,000; net income before taxes \$3,126,600,000; Federal income tax \$747,100,000. Net income \$2,379,500,000.

Statement obtained from Securities and Exchange Commission. Prepared from statement(s) by Accountant: Deloitte & Touche LLP, Raleigh, North Carolina.

**ACCOUNTANT'S OPINION**

A review of the accountant's opinion indicates the financial statement meets generally accepted accounting principles and the audit contains no qualifications.

The net worth of this company includes intangibles.

Other long term liabilities consist of long-term debt, deferred income taxes & other tax liabilities, other liabilities and noncontrolling interest.

The report was updated using information the company filed with the Securities and Exchange Commission.

**KEY BUSINESS RATIOS**

**Statement date:** DEC 31 2021  
**Based on this number of establishments:** 17

<b>Firm</b>		<b>Industry Median</b>		<b>Quartile Rank (Supplier)</b>
Return of Sales:	14.8	Return of Sales:	( 34.1)	1
Current Ratio:	1.9	Current Ratio:	5.6	4
Quick Ratio:	1.3	Quick Ratio:	3.1	3
Assets / Sales:	126.5	Assets / Sales:	278.2	1
Total Liability / Net Worth:	98.4	Total Liability / Net Worth:	55.3	4

## PUBLIC FILINGS

The following Public Filing data is for information purposes only and is not the official record. Certified copies can only be obtained from the official source.

## JUDGMENTS

<b>Status:</b>	<b>Unsatisfied</b>
<b>DOCKET NO.:</b>	201100200625
<b>Judgment type:</b>	Judgment
<b>Against:</b>	LABORATORY CORPORATION OF AMERICA HOLDINGS and OTHERS
<b>In favor of:</b>	ALLIGOOD, MARK, LEVITTOWN, PA ALLIGOOD, KAREN, LEVITTOWN, PA
<b>Where filed:</b>	PHILADELPHIA COUNTY COMMON PLEAS COURT, PHILADELPHIA, PA
<b>Date status attained:</b>	10/14/2011
<b>Date entered:</b>	10/14/2011
<b>Latest Info Received:</b>	10/18/2011

## SUITS

<b>Status:</b>	<b>Pending</b>
<b>DOCKET NO.:</b>	201700000288
<b>Plaintiff:</b>	SPATOULAS, GEORGE, H W, WILMINGTON, DE SPATOULAS, VALERIE, WILMINGTON, DE
<b>Defendant:</b>	LABORATORY CORPORATION OF AMERICA HOLDINGS AND OTHERS
<b>Where filed:</b>	DELAWARE COUNTY PROTHONOTARY, MEDIA, PA
<b>Date status attained:</b>	01/12/2017
<b>Date filed:</b>	01/12/2017
<b>Latest Info Received:</b>	01/20/2017

<b>Status:</b>	<b>Pending</b>
<b>CASE NO.:</b>	01-CV-2015-902391.00
<b>Plaintiff:</b>	MARSHALL CAITLYN
<b>Defendant:</b>	LABORATORY CORPORATION OF AMERICA HOLDINGS
<b>Cause:</b>	Malpractice
<b>Where filed:</b>	JEFFERSON COUNTY CIRCUIT COURT/BIRMINGHAM, BIRMINGHAM, AL
<b>Date status attained:</b>	06/16/2015
<b>Date filed:</b>	06/16/2015
<b>Latest Info Received:</b>	08/10/2015

<b>Suit amount:</b>	<b>\$477</b>
<b>Status:</b>	<b>Pending</b>
<b>CASE NO.:</b>	14CVM1416
<b>Plaintiff:</b>	MATTHEW AND CANDACE BARONI
<b>Defendant:</b>	LABORATORY CORP. OF AMERICA HOLDINGS
<b>Cause:</b>	MONEY OWED
<b>Where filed:</b>	MAGISTRATE COURT, BURLINGTON, NC
<b>Date status attained:</b>	06/16/2014
<b>Date filed:</b>	06/16/2014
<b>Latest Info Received:</b>	07/16/2014

If it is indicated that there are defendants other than the report subject, the lawsuit may be an action to clear title to property and does not necessarily imply a claim for money against the subject.

## UCC FILINGS

**Collateral:** Leased Inventory and proceeds - Chattel paper and proceeds  
**Type:** Original  
**Sec. party:** CISCO SYSTEMS CAPITAL CORPORATION, SAN JOSE, CA  
**Debtor:** LABORATORY CORPORATION OF AMERICA HOLDINGS  
**Filing number:** 2008 0840866  
**Filed with:** SECRETARY OF STATE/UCC DIVISION, DOVER, DE

**Date filed:** 03/10/2008  
**Latest Info Received:** 04/09/2008

**Type:** Continuation  
**Sec. party:** CISCO SYSTEMS CAPITAL CORPORATION, SAN JOSE, CA  
**Debtor:** LABORATORY CORPORATION OF AMERICA HOLDINGS  
**Filing number:** 2013 0798612  
**Filed with:** SECRETARY OF STATE/UCC DIVISION, DOVER, DE

**Date filed:** 02/28/2013  
**Latest Info Received:** 04/26/2013  
**Original UCC filed date:** 03/10/2008  
**Original filing no.:** 2008 0840866

**Type:** Continuation  
**Sec. party:** CISCO SYSTEMS CAPITAL CORPORATION, SAN JOSE, CA  
**Debtor:** LABORATORY CORPORATION OF AMERICA HOLDINGS  
**Filing number:** 2018 1581004  
**Filed with:** SECRETARY OF STATE/UCC DIVISION, DOVER, DE

**Date filed:** 03/07/2018  
**Latest Info Received:** 04/30/2018  
**Original UCC filed date:** 03/10/2008  
**Original filing no.:** 2008 0840866

**Collateral:** Account(s) including proceeds and products - Chattel paper including proceeds and products - General intangibles(s) including proceeds and products - Leased Fixtures including proceeds and products - Leased Equipment including proceeds and products  
**Type:** Original  
**Sec. party:** REGIONS COMMERCIAL EQUIPMENT FINANCE, LLC, BIRMINGHAM, AL  
**Debtor:** LABORATORY CORPORATION OF AMERICA HOLDINGS  
**Filing number:** 2013 1927087  
**Filed with:** SECRETARY OF STATE/UCC DIVISION, DOVER, DE

**Date filed:** 05/20/2013  
**Latest Info Received:** 06/14/2013

**Collateral:** Account(s) including proceeds and products - Chattel paper including proceeds and products - General intangibles(s) including proceeds and products - Leased Fixtures including proceeds and products - Leased Equipment including proceeds and products  
**Type:** Original  
**Sec. party:** REGIONS COMMERCIAL EQUIPMENT FINANCE, LLC, BIRMINGHAM, AL  
**Debtor:** LABORATORY CORPORATION OF AMERICA HOLDINGS  
**Filing number:** 2013 1610592  
**Filed with:** SECRETARY OF STATE/UCC DIVISION, DOVER, DE

**Date filed:** 04/26/2013  
**Latest Info Received:** 05/24/2013

There are additional UCC's in D&B's file on this company available by contacting 1-800-234-3867.

The public record items contained in this report may have been paid, terminated, vacated or released prior to the date this report was printed.

## GOVERNMENT ACTIVITY

### Activity summary

Borrower (Dir/Guar):	NO
Administrative debt:	NO
Contractor:	YES
Grantee:	NO
Party excluded from federal program(s):	NO
Congressional District:	06

The details provided in the Government Activity section are as reported to Dun & Bradstreet by the federal government and other sources.

---

Copyright 2022 Dun & Bradstreet - Provided under contract for the exclusive use of subscriber 263159923